Key result
Captopril protected nigrostriatal dopamine neurons from degeneration and reduced microglia activation in acute and chronic rodent models of Parkinson's disease.
Why the study?
Does captopril protect nigrostriatal dopamine neurons in animal models of parkinsonism?
Population
Animal models of parkinsonism
Design
Preclinical
Authors
Loading...
No change to Parkinson's management; leaves open AngII pathway as therapeutic target pending human data.
Does captopril protect nigrostriatal dopamine neurons in animal models of parkinsonism?
Captopril demonstrates neuroprotective effects on nigrostriatal dopamine neurons in rodent models of Parkinson's disease, suggesting the brain AngII pathway as a potential therapeutic target.
Sonsalla et al. (2013) studied Parkinson's disease (animal models). Captopril was evaluated on Protection of nigrostriatal dopamine neurons. Captopril protected nigrostriatal dopamine neurons from degeneration and reduced microglia activation in acute and chronic rodent models of Parkinson's disease.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: